2024-11-05 - Analysis Report
##  Merck & Co Inc (MRK) Stock Analysis

**1. Performance Comparison:**

Merck & Co Inc (MRK) is a pharmaceutical company that develops, manufactures, and markets a broad range of prescription medicines, vaccines, and animal health products. 

MRK has generated a cumulative return of 58.01% compared to the S&P 500 (VOO) which has returned 131.28%. This puts MRK at a -73.27% divergence from the benchmark, meaning it has underperformed the S&P 500 significantly. While the relative divergence is 12.37%, indicating it sits in the lower 12.37% percentile of historical divergence, the overall performance suggests that MRK has lagged behind the broader market. 

**Alpha and Beta Analysis:**

| Year | CAGR | MDD | Alpha | Beta |
|------|------|----------|-----|------|
| 2015 | -7.6% | 18.1% | -6.9% | 1.0 |
| 2016 | 12.2% | 8.7% | 0.8% | 0.9 |
| 2017 | -6.5% | 17.0% | -25.1% | 0.5 |
| 2018 | 35.9% | 12.6% | 42.9% | 0.7 |
| 2019 | 20.3% | 12.1% | -8.3% | 0.7 |
| 2020 | -11.1% | 27.2% | -26.3% | 0.7 |
| 2021 | -0.8% | 19.8% | -29.6% | 0.3 |
| 2022 | 44.3% | 10.4% | 64.3% | 0.3 |
| 2023 | -1.9% | 14.0% | -26.7% | 0.2 |
| 2024 | -10.0% | 22.4% | -30.7% | 0.2 |

The analysis reveals a volatile performance with varying alpha and beta values. While 2018 and 2022 saw strong positive alpha, indicating outperformance compared to the benchmark, other years like 2015, 2017, and 2020 show negative alpha, indicating underperformance. The beta fluctuates as well, demonstrating inconsistent sensitivity to market movements. 

**2. Recent Price Movements:**

* Last-market price: 101.88
* 5-day Moving Average: 102.93
* 20-day Moving Average: 106.8
* 60-day Moving Average: 112.42

The stock is currently trading below its 5, 20, and 60-day moving averages, indicating a downtrend. The significant gap between the current price and the 60-day moving average indicates a potential for further decline. 

**3. Technical Indicators:**

* RSI: 12.73
* PPO: -0.33
* Delta_Previous_Relative_Divergence: -10.0 (Short-term decline)
* Expected Return: 0.0%

The RSI value suggests the stock is in oversold territory, which could potentially indicate a rebound. However, the negative PPO and declining relative divergence signal continued downward pressure on the stock. The expected return of 0.0% suggests that over the long term (2+ years), the stock is not expected to outperform the S&P 500.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-05 | 2.15 | 16.11 B$ |
| 2024-05-03 | 1.88 | 15.78 B$ |
| 2023-11-03 | 1.87 | 15.96 B$ |
| 2023-08-07 | -2.35 | 15.04 B$ |
| 2024-08-05 | -2.35 | 15.04 B$ |

The most recent earnings report for the quarter ending 2024-08-05 showed EPS of 2.15 and revenue of $16.11B. While revenue continues to be robust, EPS has been fluctuating, and the most recent report shows a significant improvement compared to previous quarters. However, specific analysts' expectations and predictions need to be assessed for a comprehensive understanding of the current earnings performance.

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---|---|---|
| 2024-06-30 | $16.11B | 76.76% |
| 2024-03-31 | $15.78B | 77.56% |
| 2023-12-31 | $14.63B | 73.26% |
| 2023-09-30 | $15.96B | 73.29% |
| 2023-06-30 | $15.04B | 73.24% |

MRK exhibits consistently high profit margins, indicating strong profitability. The company's revenue has been growing steadily over the last year, demonstrating its strong market position.

**2) Capital and Profitability:**

| Quarter | Equity  | ROE |
|---|---|---|
| 2024-06-30 | $43.58B | 12.52% |
| 2024-03-31 | $40.36B | 11.80% |
| 2023-12-31 | $37.58B | -3.26% |
| 2023-09-30 | $41.25B | 11.50% |
| 2023-06-30 | $38.69B | -15.44% |

MRK demonstrates solid equity, but the ROE is fluctuating, indicating inconsistent returns on shareholder capital. The negative ROE in 2023 Q4 and Q2 highlights the challenging market conditions and potential concerns regarding profitability.

**6. News and Recent Issues:**

* **Recent Earnings Release:** While the earnings report for the quarter ending 2024-08-05 showed positive results, it's crucial to review analysts' expectations and projections for a complete picture. 
* **Market Outlook:** Investors should assess recent news and reports related to MRK's pipeline, competitor activities, and overall market trends to gain a better understanding of the company's future performance.
* **Analyst Opinions:** Refer to platforms like FINBOLD and other financial news websites for insights into current analyst ratings, price targets, and overall sentiment towards MRK.

**7. Comprehensive Analysis:**

Overall, MRK faces challenges due to underperformance against the benchmark, declining prices, and fluctuating profitability. While the most recent earnings report showed positive signs, the company's long-term performance remains uncertain, with expected returns not exceeding the market average. 

**8. English Report:**

MRK has shown a significant divergence from the S&P 500 in recent times, with a cumulative return of 58.01% compared to the benchmark's 131.28%. While its recent earnings have shown positive results, the stock's current performance is characterized by a downtrend, reflected in its price movements and technical indicators. The stock is currently trading below its moving averages and shows signs of potential further decline. Its RSI suggests oversold territory, which could indicate a rebound, but the negative PPO and declining relative divergence suggest continued downward pressure. Further analysis of the earnings report and market outlook, alongside analyst opinions, is crucial to assess the company's long-term trajectory. It is important to consider the company's consistent high profit margins and steady revenue growth. However, the fluctuating ROE and challenging market conditions suggest that MRK faces challenges in maintaining consistent returns for its shareholders. Ultimately, investors should conduct thorough research and assess their individual risk tolerance before making any investment decisions related to MRK. 
